Meridian Bioscience (VIVO) Misses Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.82 +7.22%
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED: -84.82M
Today's EPS Names:
NHTC, SKHY, GEHC, More
Financial Fact:
AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED: -84.82M
Today's EPS Names:
NHTC, SKHY, GEHC, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $47.1 million versus the consensus estimate of $46.6 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fortinet (FTNT) Tops Q3 EPS by 5c, Offers Guidance
- Mid-America Apartment (MAA) Misses Q3 EPS by 5c ; Offers Guidance
- VIST Financial Corp. (VIST) Misses Q3 EPS by 14c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
